• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • BioAsia 2023 to be held in February 24-26 in Telangana, India
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian?
  • Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE
  • Event: Australia’s biggest week in biotech kicks off in Perth
  • $3 trillion growth reported for biotech sector in USA
  • Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect”
  • Vaccination, Rising Deaths, And The False Narrative
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    July 26, 2022

    We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO

    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»BioEvents»Event Report – Panel Discussion on Pharma & Biopharma Industries in India: Opportunities & Challenges in Innovative Drug Discovery & Development

Event Report – Panel Discussion on Pharma & Biopharma Industries in India: Opportunities & Challenges in Innovative Drug Discovery & Development

0
By Biotech Express on April 23, 2021 BioEvents

The Panel Discussion on “Pharma and Biopharma Industries in India: Challenges and Opportunities in Innovative Drug Discovery and Development” was conducted as a part of the concluding session of the virtual workshop on “Drug Discovery and Development” from 15th March to 4th April 2021 by the Federation of Asian Biotech Associations (FABA) (biofaba.org.in), the Science Gurus (sciencegurus.org) and the University of Hyderabad (uohyd.ac.in). The workshop participants included undergraduate students, postgraduates, research and postdoctoral scholars, and research scientists from universities, research institutions and Pharma/biotech industries across India, Bangladesh, Israel and Iran. The highlights of the workshop were the exceptional speakers who participated from both India and the US and presented breakthrough advances in the field of drug discovery and development.

Panelists :
1. Anand Anandkumar (CEO, Bugworks)
2. Dr. Tanjore Balganesh (President, GangaGen)
3. Dr.Srikar Raman (VP and Head R&D, Levim Biotech)
4. Dr. Manish Diwan (Head – Strategy Partnership & Entrepreneurship Development, BIRAC)
5. Dr. Nishith Tyagi (Director, AI and Data Science,
Novartis)

Moderator: Dr. Uday Saxena, ReaGene Innovations

Other Contributors:
Professor P. Reddanna (University of Hyderabad)
Dr. Ajith Kamath (Advisor Pandorum Technologies) and
Dr. Bindu Madhava Reddy (Assistant Professor, University of Hyderabad)

Q1: India has done very well in development of generic and biosimilars. However, we have not produced an innovation-based first in class medicine yet. Please name one reason for this and a possible solution

Anand:
Innovation takes funds and risk-taking ability but Indian Biopharma still does not have that ecosystem yet. Secondly the supply of validated targets that can be used in drug discovery come from Academia and Industry collaboration in the USA, but no such activity is prevalent in India. This is a big gap in Indian Innovation ecosystem. Things are changing and will get better soon but, we are not there yet.

Nishith
The risk-taking ecosystem is not there in India. Secondly, academia normally leads the way in innovative science, where India is still lagging. Disease biology and medical science towards innovation is lacking in India and unless we work more in this area we will lag behind.

Balganesh
We tend to work in silos, there is hardly any cross disciplinary interaction between biology and say, chemistry. This is important for translational and product research. The second aspect is that we do not have clinicians participate in the innovation process, either in understanding disease biology or in epidemiology. The third point is that our best brains are post-doctoral candidates in the US and tend to stay there.

Srikar
There is no dearth of funding in India – our generics and biosimilar sales are huge and we are the third largest economy in the world. Also, our young talent is very good, but we do not have experienced people in the Indian regulatory system or guidelines to assess and support innovative approaches to treat diseases. We need feedback from them and need positive but critical advice from them. We have to be patient and things will improve and the biopharma will grow.

Manish
The status of first in class discovery in India is pathetic. Preclinical discovery and clinical development form two pillars of innovation. We do not have much experience in clinical development – as seen by our product pipeline, hardly few molecules are in clinical development. We need larger numbers in clinical development. The experience that we have acquired in biosimilar space is excellent and clinical development of novel drugs should follow a similar pathway. We can expect to see many large international pharma companies set up shop here and that will help us.

Q2: Is our academic training good enough to support Innovative and translational science?

Anand:
Few years back when we looked at the PhD talent pool for industry it was not very good, but quality is improving. our scientists have to think about data, ability to comprehend and use data. They have to think like a startup and think in a big picture and explore getting training in data sciences as a tool.

Nishith:
We have excellent QA scientists and they all come from academia but still not ready for the future. We should be offering integrated courses that involve computer training very early. Secondly, medical institutions have to be involved to provide a clinical perspective. Finally, AI/ML skills need to be included in the drug discovery process to absorb the vast amount of information that is out there. So, students need to be trained in AI/ML as well as exposure medical sciences.

Balganesh:
We are not there yet – but we can get there. Late 80’s there was no value attached to patents, but slowly patenting is improving. But its only being done as a mandatory activity without understanding the importance. This has to change. Secondly, in the past there were a handful of Institutions that trained talent pools very well and the number is still small. One element is rotational training of PhDs across discipline like it is done in the USA. Finally, we need to have academia go work at the industry and create a highway of knowledge sharing.
Srikar
PhD trains you to do research, it’s an enabling tool but not means to innovation excellence. What is needed is a leader/mentor who can see the big picture and bring everything together and think uniquely. It’s not just PhD but focus has to be on training in innovation skills.

Manish
Twenty years ago I did a postdoc in South Korea. It was eye opening because every faculty there had links with industry and had a spin off. Similarly, in Japan, PI who did not have industry collaboration was looked down upon. This is something we need to have in Indian academies, without which quality exposure to innovation will not be there. We have very few students/PIs in India that venture into new areas but spend their lifetime working on the same problem. However newer and younger faculty are aggressive and are more collaborative and students from such labs are better prepared. The Government now tends to fund multidisciplinary and industry connected projects.

Dr. Reddanna
A number of academic institutions in the country with highly qualified faculty and excellent infrastructure are working on various biomedical problems but they have very limited interactions with industry due to lack of push from academia and pull from industry. Secondly, no institution has medical schools attached, which is critical for innovation research. This is a major challenge in pushing biomedical ideas into products. Industry in India is risk averse and thus have very limited opportunities for fresh PhDs for innovative research. In contrast, in the IT industry, in view of plenty of opportunities, they recruit and train fresh students and make a productive workforce.. BIRAC has helped a large number of start-ups and that’s where young scientists are getting training. But startups are not funded deep and VC funding is needed for further development of their innovative products However, Venture financing ecosystem is yet to evolve in India.

Anand
We need a triangle of three sections to come together – regulatory, funding and we need to hear from Indian big pharma why there is a lack of interest in innovation.

Dr. Bindu M. Reddy
Clinicians do not have an opportunity to interact and train in research. Very few discoveries are happening in the world so let’s not harp on it. Instead, let’s not focus on it alone but focus on providing BIG grants to younger scientists to train them rather than fund huge grants to established PI’s. INSPIRE fellowships can be given to clinicians and young minds.

Selected suggestions from Q/A
1. Pallavi – Industry internship is needed for young students
2. Balganesh/Anand – smaller companies can partner with CRO’s to provide fully integrated programs
3. Abhishek- what is industry ready mean for a PhD ?- Srikar suggested problem solvingskills as a key and look for jobs that are aligned with your interests and training. Anand suggested that be open to change and newer skill learning
4. Meenakshi – training in coding, etc. is critical even for biologists but not available as a course right now
5. Manish – New educational policy to be rolled out soon where interdisciplinary skills can be included into one degree
6. Jagan – should we focus on affordable medicines or high-risk innovation – Nishith favors going to breakthrough innovation/ precision medicines and be game changers despite the challenges. Commercially new drugs are far more profitable than generics which can fuel innovation. Anand says a judicious mix of both to solve our own Indian problems
7. Balganesh– Industry wants people who can think laterally and practice how you approach a problem
8. Dr. Reddanna – there is a skill gap between academia and industry needs and FABA academy was designed to fill this void thru training courses
9. Jagat -Corporate in India should have training internships like in the USA
10. Ajith – Many CROs are doing their own drug discovery in India now
11. Ajith – How to go from basic science to product innovation for young scientists? It’s mainly your interest and passion for the field of R&D, if you have a good idea or data just present it at the interview.

Major Take home messages:

1. It is important that we don’t deny the existence of an innovation ecosystem in the country. It will take time to mature to bear fruits all year long. The ecosystem is evolving and several sporadic examples of bio-innovations can be seen – Covaxin, various covid and AMR diagnostic kits, Hanugen, Aten Porus, Rotavac, many clinical leads developed from India’s BMS labs, various clinical leads developed from India’s pharmas/CROs – Daiichi Sanyo, Zydus, Rhizen, Syngene, Jubilant, to name a few.
2. Clinicians/Hospitals need to be involved in innovation process along with the basic scientists to work on disease biology
3. Both industry and academia have to work together to promote this ecosystem thru collaborations to create knowledge and skill highways
4. Regulatory and clinical development skills/pathways are not well established in India hampering novel product development
5. Training of young scientists for innovation has to be more well-rounded and include interdisciplinary education, internships at Industry and working at start-ups

The readers can also view the panel discussion on You tube, using the following link:

 

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

BioAsia 2023 to be held in February 24-26 in Telangana, India

Event: Australia’s biggest week in biotech kicks off in Perth

Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect”

Leave A Reply Cancel Reply

Current Issue – October 2022
Upcoming Event

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • BioAsia 2023 to be held in February 24-26 in Telangana, India January 10, 2023
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt November 10, 2022
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian? November 1, 2022
  • Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE October 31, 2022
  • Event: Australia’s biggest week in biotech kicks off in Perth October 26, 2022
  • $3 trillion growth reported for biotech sector in USA October 25, 2022
  • Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect” September 21, 2022
  • Vaccination, Rising Deaths, And The False Narrative September 20, 2022
  • Guestorial: Genome Mapping Techniques and its Application in Aquaculture September 19, 2022
  • Bombay HC Issues Notice To Bill Gates, Serum Institute, DGCI, Others Over Plea On Alleged ‘Vaccine Death’ September 5, 2022
  • Deaths due Covid-19 vaccines should be compensated by vaccine makers: Expert hope on Kerala HC remark August 21, 2022
  • Maker of Dolo-650, pandemic’s ‘magic pill’, faces income tax searches and PIL petitions August 20, 2022
  • Anthony Fauci, Controversial US Top-doc FINALLY, To Retire By Year-end August 20, 2022
  • SII’s Cervevac: The new DCGI approved vaccine without published clinical trial results August 20, 2022
  • Pitch your Start-up to National/International Venture Capitalists – first ever opportunity provided to Bio-Start-ups by FABA August 19, 2022
  • India’s Clinical Trial Registry might disappear soon and so the history of pharma record August 19, 2022
  • Nearly Half of Pregnant Women in Pfizer Trial Miscarried August 10, 2022
  • Researchers develop Cellulose shoes made by bacteria August 9, 2022
  • Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility August 5, 2022
  • CBI Arrests of CDSCO officials, a Biocon official & Intermediaries in an alleged bribery case exposed Corruption in Govt and Pharma sector July 27, 2022
  • We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO July 26, 2022
  • EVENT HIGHLIGHTS: Genome editing as a novel technology for sustainable development July 24, 2022
  • US Military Doctor Testifies under Oath That She Was ORDERED To ‘Cover up’ COVID Vaccine Injuries July 24, 2022
  • Climatic Effect on Marine Biodiversity and their impact on coral reefs July 23, 2022
  • Highlights of India’s first Biotech startup Expo June 13, 2022
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity June 6, 2022
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds May 30, 2022
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft May 26, 2022
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak May 25, 2022
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid May 25, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.